Navigation Links
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Date:10/3/2007

p>"These findings provide further evidence of the role of IL-12/23 in the pathogenesis of psoriasis and the promise that a new therapeutic approach like ustekinumab may hold for dermatologists and their patients living with this chronic, immune-related disease," said Craig Leonardi, MD, St. Louis University Medical School and lead investigator of the study. "The efficacy and safety data for ustekinumab in the treatment of psoriasis are exciting for the dermatology community."

At week 12 of this Phase 3, multicenter, randomized, double-blind, placebo-controlled trial, 67 percent of patients treated with 45 mg ustekinumab (two 45 mg doses four weeks apart) and 76 percent of patients treated with 90 mg ustekinumab (two 90 mg doses four weeks apart), achieved PASI 75 compared with four percent of patients receiving placebo (P < 0.001 for each comparison versus placebo). Also at week 12, 42 percent of patients in the 45 mg ustekinumab dosing group and 51 percent of patients in the 90 mg ustekinumab dosing group achieved PASI 90, or nearly complete clearance of psoriasis, compared with one percent of patients receiving placebo (P < 0.001 for each comparison versus placebo). Similar response rates were observed in the placebo group 12 weeks after crossover to treatment with ustekinumab. After one additional dose at week 16, responses were maintained through week 28, which is consistent with the maintenance regimen of every 12-week dosing currently being evaluated in the Phase 3 program. Improvements in clinical measures were paralleled with improvements in quality of life measures.

"These findings show that by targeting IL-12/23 with ustekinumab, we may be able to offer dermatologists and patients a new, promising biologic therapy with an infrequent dosing regimen for the treatment of psoriasis," said Jerome A. Boscia, MD, senior vice president, Clinical Research and Development, Centocor, Inc. "We are encouraged by the results from the Phase 3 program and look
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
5. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- The Centers for Medicare & Medicaid Services (CMS) ... Organization (QIN-QIO) contract to a partnership led by the ... 1, WVMI will launch Quality Insights Quality Innovation Network ... Pennsylvania , Delaware , ... will engage providers and the community in multiple, data-driven ...
(Date:7/23/2014)... 2014 Research and Markets   ... Electrophysiology Ablation Catheters Market 2014-2018" report to ... Catheter ablation is a minimally ... electrical pathways from sections of the heart that ... arrhythmias). Cardiac arrhythmias can be of several types, ...
(Date:7/23/2014)... -- Creekridge Capital, an independent vendor-focused finance company, ... far in 2014 to their portfolio of contractual ... both the healthcare and technology industries. They range ... companies. Each of these new vendors take advantage ... standard leasing products, subscription solutions, a dedicated revolving ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3Creekridge Capital Signs Several New Vendor Partners 2
... Sigma-Aldrich (Nasdaq: SIAL ) announced today that it ... leader in bench top flow chemistry instruments, the terms ... of approximately 400 CatCart® catalyst products for flow chemistry ... and CatCart catalyst cartridges provide organic chemists in academic ...
... Accumetrics, Inc., developer and marketer of the VerifyNow® ... measuring an individual,s response to multiple antiplatelet agents, announced ... that will raise $16.5 million in new capital. ... into 2011, came from the company,s existing investors, including ...
Cached Medicine Technology:Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market 2Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market 3Accumetrics Announces $16.5M in New Capital Financing 2Accumetrics Announces $16.5M in New Capital Financing 3
(Date:7/23/2014)... AidJoy is delighted to announce that it ... on September 5, 2014 from 7:00 to 11:00 p.m. ... expected to attend this semi-formal event. , "We are elated ... six years," says Jess Dennis, Director of Operations and organizer ... this moment in AidJoy’s history before we launch into our ...
(Date:7/23/2014)... The European Bio fertilizers Market Report ... with analysis and forecast of revenue. The bio fertilizers ... $ 2,566.4 million in 2012 to $4,582.2 million by ... 2017. , Browse through the TOC of the European ... the in-depth analysis provided. , http://www.micromarketmonitor.com/market/europe-bio-fertilizer-4637178345.html ...
(Date:7/23/2014)... "I wanted a better way to keep track of all ... pressure and pulse rate," said an inventor from Long Beach, ... a bunch of different devices, so I invented one that ... to make it easier to monitor health conditions. The invention ... enables the user to have more control over his or ...
(Date:7/23/2014)... 2014) Statins, a class of drugs commonly used ... of developing Barrett,s esophagus, according to a new study ... official journal of the American Gastroenterological Association. Obese patients ... use. , "Patients who received statins had a 43 ... compared to non-users," said study author Hashem B. El-Serag, ...
(Date:7/23/2014)... some high-profile athletes who suffered repeated blows to the ... their brains. Those clumps suggest the athletes had a ... working on tests that might be able to detect ... in Chemical & Engineering News (C&EN) , the ... In the article, Lauren Wolf, a senior editor at ...
Breaking Medicine News(10 mins):Health News:AidJoy’s Inaugural Gala to be Held September 5, 2014 2Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 2Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 3Health News:Europe Bio Fertilizer Market is Expected to Reach $4,582.2 Million in 2017 - New Report by MicroMarket Monitor 4Health News:Statin use decreases the risk of Barrett's esophagus 2
... Oct. 15 (HealthDay News) -- Women in their 40s who are ... for having mammograms to 50 may find clarity in a new ... save lives. "The bottom line is everyone over the age ... chief of breast imaging at Lenox Hill Hospital in New York ...
... higher intake of alcohol during pregnancy adversely affects the ... other problems in the child. However, most recent ... light drinking by the mother during pregnancy. The ... factors of the mother may have large effects on ...
... prodigious precursors of all the tissues in our body, ... unfortunately, cancer. Now research from Rockefeller University shows that ... live for too long, can increase the odds of ... cell death in precursor cells for blood, or hematopoietic ...
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Oct. 14 ... may help alleviate the symptoms of fibromyalgia, a small study ... syndrome, were enrolled in a two-hour yoga class that met ... women diagnosed with the condition were put on a waiting ...
... Gardner HealthDay Reporter , THURSDAY, Oct. 14 ... of lovelorn Stanford undergrads, researchers discovered that high-octane romantic ... effect isn,t just that the person is distracted by ... too. Instead, the researchers found that feeling "head-over-heels" activates ...
... is available in Spanish . Researchers a ... Nuclear Medicine, Hospital Virgen de las Nieves at Granada found ... of a structural analog of glucose labeled with a positron-emitting ... relatively rare disease with high mortality rates among most patients ...
Cached Medicine News:Health News:Latest Findings Back Mammograms for Women in Their 40s 2Health News:Latest Findings Back Mammograms for Women in Their 40s 3Health News:2 studies present new data on effects of alcohol during pregnancy 2Health News:Gene identified that prevents stem cells from turning cancerous 2Health News:Gene identified that prevents stem cells from turning cancerous 3Health News:Yoga May Combat Fibromyalgia Symptoms 2Health News:Yoga May Combat Fibromyalgia Symptoms 3Health News:Yoga May Combat Fibromyalgia Symptoms 4Health News:Romantic Love: Nature's Painkiller? 2Health News:Romantic Love: Nature's Painkiller? 3Health News:New method is found for accurate diagnosis of gall bladder cancer, 1 of the most deadly 2
Surgical Stainless Steel Adult 16.5....
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
FlexiSlip™ Plastic coated malleable metal core. Single use, Sterile, Latex Free. Soft distal tip flexes to reduce risk of trauma to patient. Malleable metal core is easy to shape. Low friction ...
Medicine Products: